CLICK CAR Breakthrough Modular CAR Technology

A revolutionary approach to chimeric antigen receptor (CAR) T-cell therapy, utilizing innovative Split-CAR technology that offers unparalleled versatility and enhanced efficacy. Our proprietary Split-CAR system seamlessly integrates with both allogeneic and autologous T cells, enabling the development of personalized therapies tailored to individual patients.

✅ Breakthrough Modular CAR Technology – Click-CAR enables a universal, controllable, and multiantigen targeting CAR platform, intended to reduce tumor escape and relapse risks

✅ Proven In-Vitro Success – High-efficiency trans-splicing (87%+ yield) and robust tumor cell clearance (>50% reduction in target tumor cell population within 24 hours), demonstrating strong cytotoxicity

✅ No Negative Impact on T-Cell Function – Engineered T-cells maintain normal proliferation and memory phenotype, with no apparent toxicity observed in in-vitro assays

✅ Switchable CAR Approach – On-demand activation could minimize toxicity (e.g., CRS) by allowing precise control of CAR activity via ligand administration

✅ High Manufacturing Scalability – Works with autologous & allogeneic cells, enabling an off-the-shelf CAR-cells stock for faster, cost-effective clinical applications.